Following a request from the companies concerned and, where relevant, after an evaluation by the Agency, the lists already published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017 were updated on 10 December 2021. Specifically, the update concerns the lists of allergens for specific immunotherapy and diagnosis for which companies may continue the procedure for obtaining a marketing authorisation (Annex 1), for which the Agency has issued a refusal to continue the procedure (Annex 2) and for which companies have waived the procedure for obtaining a marketing authorisation (Annex 3).